Details of the Drug Combination

General Information of Drug Combination (ID: DCHWSKP)

Drug Combination Name
Remdesivir Favipiravir
Indication
Disease Entry Status REF
Covid19 Phase 3 [1]
Component Drugs Remdesivir   DMBFZ6L Favipiravir   DMBZ27L
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Remdesivir
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Approved [2]
Ebola virus infection 1D60.0 Phase 1 [3]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [4]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [4]
Remdesivir Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
MERS-CoV RNA-directed RNA polymerase (RdRp) TTOA6YT R1AB_CVEMC (4378-5310) Inhibitor [4]
SARS-CoV RNA-directed RNA polymerase (RdRp) TTKXI53 R1AB_CVHSA (4370-5301) Inhibitor [4]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [7]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [2]
------------------------------------------------------------------------------------
Remdesivir Interacts with 14 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [8]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Expression [8]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Expression [8]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [8]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [8]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [8]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Decreases Expression [8]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [8]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Phosphorylation [8]
Lysosomal protective protein (CTSA) OT167UBM PPGB_HUMAN Increases Hydrolysis [9]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Increases Hydrolysis [9]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Hydrolysis [9]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Increases Hydrolysis [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DOT(s)
Indication(s) of Favipiravir
Disease Entry ICD 11 Status REF
Influenza virus infection 1E30-1E32 Approved [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Favipiravir Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU Modulator [10]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Complication of Medical Care DCEI7Q7 N. A. Phase 1 [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04694612) Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
7 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
8 An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
9 Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. Chem Biol Interact. 2022 Jan 5;351:109744. doi: 10.1016/j.cbi.2021.109744. Epub 2021 Nov 11.
10 Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
11 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.
12 ClinicalTrials.gov (NCT04727775) Antiviral Drugs on the Treatment of SARS-CoV-2